Background: Identification of clinical and molecular biomarkers to predict dynamic
response or monitor in real-time the efficacy of antiangiogenic therapy represents a
major point in the treatment of patients with advanced colorectal cancer. Several studies
have been conduced to identify some predictive biomarkers to select patients who will benefit
from bevacizumab, the most widely used antiangiogenic monoclonal antibody.
Conclusion: After a decade since the introduction of bevacizumab, no effective predictive
biomarkers are available in routine clinical practice. In this review, we summarized the
potential candidate dynamic biomarkers that may play a role in this setting.